Highest-materiality recent filing
Vicapsys Life Sciences issues $330K note to AJB Capital, 10% interest, 8% OID, due Dec 2023
Principal $330,000, purchase price $303,600 (8% OID), 10% annual interest, maturity December 27, 2023.
Vicapsys Life Sciences dismisses auditor D. Brooks and appoints Assurance Dimensions
Board dismissed D. Brooks and Associates CPAs as independent auditor effective May 12, 2023.
Vicapsys Life Sciences appoints Federico Pier as CEO, effective Feb 15, 2022
Federico Pier appointed CEO effective Feb 15, 2022; previously interim CEO since Aug 2020 and Executive Chairman since May 2019.
appointed each of Charles “Charlie” Farrahar, Dr. Colleen Delaney and Richard Rosenblum as members of the Board.
accepted the resignations of John Potts and Michael Yurkowsky as members of the Board, effective immediately.
accepted the resignations of John Potts and Michael Yurkowsky as members of the Board, effective immediately.
appointed each of Charles “Charlie” Farrahar, Dr. Colleen Delaney and Richard Rosenblum as members of the Board.
appointed each of Charles “Charlie” Farrahar, Dr. Colleen Delaney and Richard Rosenblum as members of the Board.
On February 15, 2022, the Board of Directors (the “Board”) of Vicapsys Life Sciences, Inc. (the “Company”) appointed Federico Pier as Chief Executive Officer of the Company.
Max materiality 0.75 · Median 0.53 · Most common event other_material